Rheumatoid arthritis is an auto immune disease which requires chronotherapy as it occurs during early morning. Baricitinib used to treat rheumatoid arthritis. The aim of the present investigation was to develop chronomodulated drug delivery system of Baricitinib such that it releases the drug early in the morning, during which the symptoms of rheumatoid arthritis worsen. To develop chronomodulated drug delivery system of Baricitinib, initially core tablets of Baricitinib were prepared using three different supradisintegrants followed by coating with pH dependent polymer of Eudragit S100. The prepared core tablets are evaluated for physical parameters and an optimal system was identified. Further, coating composition of Eudragit L-100 was optimized and coating tablets of Baricitinib was prepared. The prepared coated tablets were evaluated for the in vitro release studies in 0.1N HCl, pH 6.8 phosphate buffer and pH 7.4 phosphate buffer. Formulation with 12.5% of coating solution had shown a significant drug release after a lag time of 3 h (in pH 6.8 medium), 6 h (in pH 6.8 medium) and 8 h (in pH 7.4 medium), respectively. Thus, chronomodulated drug delivery system of Baricitinib was formulated and that if a tablet is administered around 9 pm to 10 pm, the drug release starts after a lag time of 6 h i. e., around 3am to 4 am.
Impact Factor
2022: 6.012
This work is licensed under a